News for Aptose Biosciences Inc. (APS.TO)

Shares of Global Blue Group Holding AG GB rose sharply during Wednesday's pre-market trading session after the company announced it will be acquired by Shift4 f...

U.S. stock futures fell on Wednesday after scaling fresh records on Tuesday. The futures of all four benchmark indices were trading lower.

SAN DIEGO and TORONTO, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (”œAptose” or the ”œCompany”) ( APTO, TSX: APS), a clinical-stage preci

U.S. stock futures rose on Tuesday following a mixed close on Friday after the Presidents' Day holiday on Monday.

Shares of GCL Global Holdings Ltd GCL rose sharply in today’s pre-market trading. GCL and RF Acquisition Corp. disclosed the successful completion of their b...

Significant Transaction by ARMISTICE CAPITAL, LLC (Trades, Portfolio) On December 31, 2024, ARMISTICE CAPITAL, LLC (Trades, Portfolio) executed a notable transa

SAN DIEGO and TORONTO, Feb. 13, 2025 (GLOBE NEWSWIRE) — Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision o…

**media[538634]**

TUS+VEN+AZA triplet achieves Cycle 1 complete remission (CR) in TP53-mutated/CK AML

**media[511173]**

TUS+VEN+AZA triplet has potential as frontline therapy to treat large, mutationally diverse populations of AML

Shares of Rumble Inc.

Atai Life Sciences N.V. (ATAI) experienced a significant stock movement with a 5.04% rise, reaching $1.25 per share. The trading volume was 791,815 shares, with

XOMA (XOMA), a biotechnology royalty company, experienced a significant stock movement with a 5.14% increase in its share price, reaching $26.40. The trading vo

Agenus Inc. (AGEN) experienced a notable stock price increase of 5.07%, reaching $2.90 per share. The trading volume was 257,797 shares with a turnover rate of

Curis Inc (CRIS) experienced a significant stock movement with a 6.19% increase in price, reaching $3.26 per share. The trading volume was 39,453 shares, with a

Peer-reviewed publication details unique TUS mechanism of action TUS+VEN combination synthetic lethality overcomes resistance to VEN Tuspetinib prolongs s

**media[487534]**

TUS+VEN+AZA Triplet Frontline Therapy in Newly Diagnosed AML Patients Now Enrolling at U.S. Sites TUS and TUS+VEN Broadly Active Across AML Populations, with Favora…